COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt/c/EBPβ pathway and PDK1 stabilization
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Yi-Hui Wu 1 , Tzu-Hao Chang 2 , Yu-Fang Huang 1 , Chien-Chin Chen 3, 4 , Cheng-Yang Chou 1 1 Department of Obstetrics and Gynaecology, College of Medicine, National Cheng Kung University and Hospital, Tainan, Taiwan 2 Graduate Institute of Biomedical Informatics, Taipei Medical University, Taipei, Taiwan 3 Department of Pathology, Chia-Yi Christian Hospital, Chia-Yi, Taiwan 4 Department of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan, Taiwan Correspondence to: Cheng-Yang Chou, e-mail: chougyn@mail.ncku.edu.tw Keywords: epithelial ovarian carcinoma, chemoresistance, collagen type XI alpha 1, Akt, PDK1 Received: March 27, 2015 Accepted: May 28, 2015 Published: June 10, 2015 ABSTRACT Chemoresistance to anticancer drugs substantially reduces survival in epithelial ovarian carcinoma (EOC). Here, microarray analysis showed that collagen type XI alpha 1 ( COL11A1 ) is a chemotherapy response-associated gene. Chemoresistant cells expressed higher COL11A1 and c/EBPβ than chemosensitive cells. COL11A1 or c/EBPβ downregulation suppressed chemoresistance, whereas COL11A1 overexpression attenuated sensitivity to cisplatin and paclitaxel.The c/EBPβ binding site in the COL11A1 promoter was identified as the major determinant of cisplatin- and paclitaxel-induced COL11A1 expression. Immunoprecipitation and immunofluorescence showed that in resistant cells, Akt and PDK1 were highly expressed and that anticancer drugs enhanced binding activity between COL11A1 and PDK1 binding and attenuated PDK1 ubiquitination and degradation. Conversely, chemosensitive cells showed decreased activity of COL11A1 binding to PDK1 and increased PDK1 ubiquitination, which were reversed by COL11A1 overexpression. Analysis of 104 EOC patients showed that high COL11A1 mRNA levels are significantly associated with poor chemoresponse and clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944 · cited 1×
“Overexpression and/or activation of the PI3K/ Akt survival pathway have been shown to be associated with carcinogenesis in several tissue types [21–25].”
BackgroundGene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V. R., Chuang, Y. E., Khan, J., Sotiriou, C., Aprelikova, O., Yee, C. J., Zorn, K. K., Birrer, M. J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2682 · Cited by 192
Hartmann, L. C., Lu, K. H., Linette, G. P., Cliby, W. A., Kalli, K. R., Gershenson, D., Bast, R. C., Stec, J., Iartchouk, N., Smith, D. I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1673 · Cited by 141
Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study
Lisowska, K. M., Olbryt, M., Dudaladava, V., Pamuła-Piłat, J., Kujawa, K., Grzybowska, E., Jarząb, M., Student, S., Rzepecka, I. K., Jarząb, B., et al. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00006 · Cited by 97 · cited 1×
“Several studies have used gene microarrays to identify distinct genes expressed in chemoresistant EOC patients [3–6].”
Background
Cited by
The role of ubiquitination and deubiquitination in cancer metabolism
Sun, T., Liu, Z., & Yang, Q. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01262-x · Cited by 508
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“It was found that cisplatin-resistant ovarian malignancy overexpresses COL11A1 (collagen type XI α1) which increases the chemoresistance by activating tumor-favoring AKT /PDK1 pathways [253, 254].”
BackgroundThe Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 399
The Role of the Extracellular Matrix in Cancer Stemness
Nallanthighal, S., Heiserman, J. P., & Cheon, D.-J. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00086 · Cited by 344
Chemoresistance and the Self-Maintaining Tumor Microenvironment
Yeldag, G., Rice, A., & Del Río Hernández, A. (2018) · Cancers · doi:10.3390/cancers10120471 · Cited by 214
“Collagen I has been shown to promote MAPK activation in hepatocellular carcinoma cells [124], and to promote chemoresistance in ovarian cancer cells through the activation of Akt and pyruvate dehydrogenase kinase 1 (PDK1) [125].”
Background
Metadata
- Authors
- Wu, Y.-H., Chang, T.-H., Huang, Y.-F., Chen, C.-C., & Chou, C.-Y.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-06-10
- Volume
- 6
- Issue
- 27
- Pages
- 23748-23763
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2133201200
- Cited by
- 105
- References
- 5
- FWCI
- 8.19
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.